CPC C12Q 1/6883 (2013.01) [A61K 38/12 (2013.01); C12Q 1/6827 (2013.01); C12Q 1/6851 (2013.01); G01N 33/6893 (2013.01); C07K 16/40 (2013.01); C12Q 2600/156 (2013.01)] | 10 Claims |
1. A method of treating a subject having CD55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (CHAPLE), the method comprising:
selecting a subject having CD55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (CHAPLE); and
administering an effect amount of a composition comprising at least one therapeutic antibody to the subject, wherein the therapeutic antibody is eculizumab, ALXN1007, neutrazumab, Pexelizumab, ofatumumab, HuMax-CD38, TNX-558, TNX-234, or TA106, thereby treating the subject having CD55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (CHAPLE).
|